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ABSTRACT 
A majority of the 50,000 annual human rabies deaths world- 
wide occur in canine endemic regions with a large stray dog 
population. Control of the disease is hampered by cultural and 
economic realities. The high cost of imported modern tissue 
culture vaccines is the main reason why dangerous neural tis- 
sue derived products are still being used throughout the devel- 
oping world. Several studies have shown that reduced-dose 
intradermal postexposure vaccine regimens are safe, effective, 
and economical. Their use has been approved by the Rabies 
Committee of the World Health Organization. Recent well-stud- 
ied rabies vaccine treatment failures have demonstrated that 
rabies immune globulins are essential biological products that 
save lives. There is now a critical worldwide shortage of human 
and purified equine rabies immune globulins. Oral vaccination 
of stray dogs in developing countries appears promising but has 
not yet been studied on a large scale. Recent studies have 
provided better understanding of pitfalls in postexposure man- 
agement and the handling of special problems that are not 
uncommon in countries where canine rabies is enclemic. This 
essay endeavors to present the current rabies problem from the 
vantage point of an infectious diseases consultant practicing in 
a rabies endemic region of Asia. 
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Several decades ago, at an international conference on 
infectious disease, a moderator said that there are more 
scientists working with rabies than there are human rabies 
cases. This was not true then nor is it now (Koprowski 
H. Personal communication). Rabies continues to expand 
its range worldwide and there are an estimatled 50,000 
human rabies deaths every year.’ China accounts for 5,000 
of these, and India, at least 20,000.2,3 The number in Africa 
is not known. The dog is by far the most important reser- 
voir with separate zoonoses existing among bats, foxes, 
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skunks, raccoons, and wild carnivores particularly in 
Africa and the American Arctic. Research on rabies has 
experienced a recent renaissance. This resulted in the 
arrival of second generation mammalian tissue and avian 
culture rabies vaccines, recombinant as well as attenu- 
ated live virus vaccines suitable for oral vaccination of 
animals, the general recognition that rabies immune glob- 
ulins are an essential part of postexposure treatment, and 
better understanding of the dynamics of infection and 
immune induction. A revised technical report for post- 
exposure management was published by the World Health 
Organization (WHO) in 1992,* and a new edition is now 
in preparation. It should be adhered to by any health care 
worker who is confronted by a rabies exposure. How- 
ever, the management approach must be different in 
regions where canine rabies and stray dogs abound (most 
of Asia, Africa, and Central and South America) when 
compared to countries were it is a rare disease (Figures 
1 and 2). This essay does not review well-known con- 
cepts of the pathogenesis of rabies, which have been pre- 
sented elsewhere,5-7 but it presents recent developments 
in canine rabies endemic regions. 
Figure 1. Dog with furious rabies. Note irritated oral mucosa and 
broken teeth from gnawing the metal of the cage. This animal died 
within 24 hours. Another dog actually chewed her way through the 
cage wires. 
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Figure 2. Typical street scene in Bangkok with convention of stray 
dogs. 
THE STRAY, FERAL, OR COMMUNITY DOG 
The unrestricted dog is the main villain worldwide. Cats 
and other domestic animals, like man, are incidental 
hosts. Control of the dog population is hindered by cul- 
tural, religious, logistic, and fmancial restraints. Buddhists 
abhor killing dogs and even the rabies knowledgeable 
Thai population will resist efforts by canine control off- 
cers to remove stray dogs. However, mass vaccination 
campaigns are carried out in Thailand, and they are sup- 
ported by the public. Unfortunately they are not frequent 
enough and almost always consist of only one inoculation 
for the lifetime of the stray dog. The immune response 
in dogs, after one vaccination, is short lived.8-10 Most stray 
dogs have a life span of less than 2 years, and there is a 
rapid population turn-over among these animals.‘l Stray 
dogs rarely receive revaccination, which would give them 
a more lasting immune response.*-lo Animals in canine 
rabies endemic areas are subjected to frequent rabies 
challenges. Only a protective antibody titer among the 
majority of this population will control rabies. The result 
of inadequate or not frequent enough vaccination, at least 
in Thailand, is that up to 6% of dogs found rabid at 
autopsy have a reliable rabies vaccine history within 2 
years of death, and some 40% of dogs vaccinated only one 
time have lost most of their humoral immunity 4 to 6 
month later.*x9 The inoculation of the dog population in 
endemic countries with a series of at least two preex- 
posure vaccine injections (a human-like regimen) fol- 
lowed by periodic boosters may be required to effectively 
attack the rabies problem by vaccination alone. This 
would be very costly and is logistically almost impossible 
when there is a huge stray dog population. It is, how- 
ever, now being encouraged by the private sector and 
foreign embassies for owned dogs and cats in Thai1and.l’ 
Furthermore, 62% of dogs found rabid at our laboratory 
are less than 1 year old and many are puppies between 
1 and 3 months of age. New technologies to induce 
immunity in such young dogs are urgently needed in 
canine rabies endemic regions (Mitmoonpitak C. Personal 
communication and study in progress). Efforts to intro- 
duce oral dog rabies vaccination on a regular schedule in 
regions with a large stray dog population might be a bet- 
ter way. The technology is available,13-‘j but there has as 
yet been little enthusiasm for large scale canine trials of 
such a new method on the part of veterinary public 
health authorities. Oral rabies vaccination has effectively 
controlled the fox rabies epidemic in Europe and is now 
being applied to foxes in Canada and perhaps soon will 
be applied to raccoons in the United States.13-15 The prac- 
tice of first observing a dog that has bitten man, before 
starting postexposure treatment is encouraged in Amer- 
ica, Australia, and Europe, and could be accepted where 
the likelihood of such a dog being rabid is small. This is, 
however, not the case in a country where there is rabies 
among a large stray dog population and where 50% of 
dogs that have bitten man and are taken for examination 
prove to be positive for rabies on fluorescent 
microscopy. l6 There, it is mandatory to start treatment 
and discontinue it after a dog remains healthy or has been 
found laboratory negative for rabies.l’ Consideration 
whether a bite was “provoked” or “unprovoked” is, in a 
rabies endemic region, also a game of “Russian roulette.” 
Who really understands the workings of the mind of a 
dog when it bites a man? It is the author’s experience that 
a dog bite considered to have been provoked is only 38% 
less likely to come from a rabid animal than one that has 
not been considered as a provoked bite.18,‘9 
ECONOMIC ISSUES 
One postexposure rabies treatment in an adult weighing 
50 kg, not counting wound care, costs over US $1000 in 
North America. The same conventional intramuscular 
series, using equine rabies immune globulin and a second 
generation tissue or avian culture vaccine that is as potent 
and safe as the gold standard human diploid cell vaccine 
(HDCV), costs US $75 in the Thai public sector. Purified 
vero cell vaccine (PVRV), chick embryo cell vaccine 
(PCEC), and duck embryo cell vaccine (PDEV) are such 
well-studied products. Nevertheless, US $75 represents 12 
days of labor at the current minimum wage of a worker 
in Bangkok.*O The same vaccine series would be 30 to 
50% more expensive in a private sector clinic or hospi- 
tal. Over 200,000 Thais (in a population of 69 million) 
receive postexposure rabies treatment every year, and 
30% of children aged 15 years have experienced a dog 
bite in the past (Figure 3) (Phanuphak F? Unpublished). 
However, state-of-the-art postexposure treatment is not 
affordable by the majority of the population in develop- 
ing countries. They often receive no or incomplete 
treatment, occasionally even with fraudulent vaccine 
products. 21 Dangerous locally produced sheep brain tissue 
derived Semple vaccine (SV) or suckling mouse brain tis- 
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sue derived rabies vaccine (SMB) are still used widely 
throughout developing countries.’ This has led to the 
development of reduceddose intradermal postexposure 
rabies vaccination schedules.22J3 When these vaccines 
are applied with one of the second generation vaccines 
(Table l), which are already only approximately 40% of 
the cost of the first generation tissue culture vaccine 
(HDCV), a further 50% reduction of the cost of vaccina- 
tion can be achieved.20 Equine antisera can ble purified 
and pepsin digested, reducing the previous serum sick- 
ness-like reaction rate of around 40% to approximately 
1%. The rate of anaphylactic reactions with such puri- 
fied equine rabies immune globulin (ERIG) products is 
less than 1 in 40,000 and well within the range of those 
seen with many common antibiotics.23a24 Equine rabies 
immune globulin is only 20% of the cost of human rabies 
immune globulin (HRIG) in most Asian countries. How- 
ever, currently there is a worldwide shortage of ERIG, 
which is partly due to pressure by animal rights groups 
on large European producers to close their home farms.25 
Research with human and mouse monoclonal rabies anti- 
bodies is progressing, and the technology for production 
is known.2h It is almost certain that such monoclonals 
will eventually replace HRIG, but it is unlikely that they 
will be less costly than HRIG or able to replace ERIG in 
developing countries. The same can be said for emerging 
molecular technologies to manufacture antisera using 
chick embryos and even vegetables such as tomatoes 
(Dietschold B. Unpublished). 
HUMAN RABIES VACCINES IN CURRENT USE 
Table 1 lists the vaccines that are used worldwide. Vac- 
cines 1 to 4 are often referred to as “first generation tis- 
sue culture products” and vaccines 5 to 9 as “second 
generation” vaccines. The Thai Red Cro,ss Rabies 
Committee considers the first nine vaccines on this list 
Figure 3. Thai patient with facial dog bites incurred while she was ty- 
ing to feed her sick pet, which appeared apathetic and nonaggressive, 
to be comparable in potency and safety, and clinically 
interchangeable. If a traveling patient is started on a reg- 
imen using one vaccine, treatment can be continued with 
any of the other eight. If treatment has been started with 
SV or SMB, the regimen should be replaced with a full 
series of a tissue or avian product as soon as it becomes 
available. Primary hamster kidney cell vaccines (vaccines 
10 and 11) are known to be of lower potency, and in 
cases where treatment with these has been started, it 
may also be prudent to start a new course of vaccina- 
tion when a severely exposed subject comes to a higher- 
level care facility. 
Vaccine 
Table 1. Human Rabies Vaccines in Current Use 
Diluenf Volume Country of Origin Virus Strain 
1. Human diploid cell (HDCV) 1.0 mL France PM-strain 
2. Human diploid cell (HDCV) 1 .O mL Canada Alabama-street 
3. Human diploid cell (HDCV) 1 .O mL Germany PM-strain 
4. Human diploid cell (HDCV) 0.5 mL Switzerland PM-strain 
5. Purified chick embryo cell (PCEC) 1 .O mL Germany 
6. Purified chick embryo cell (PCEC) 
Fluy LP 
1 .O mL Japan 
7. Purified vero cell (PVRV) 
Fluy HP 
0.5 mL France PM-strain 
8. Purified duck embryo (PDEV) 1 .O mL Switzerland PM-strain 
9. Rhesus lung cell (RLC, adjuvanted) 1 .O mL USA 
IO. Primary hamster kidney cell (PHKC, adjuvanted) 
Kissling 
1 .O mL Russia Vnukovo 
Il. Primary hamster kidney cell (PHKC, adjuvanted) 1 .O mL China 
12. Suckling mouse brain vaccine (SMB)+ 
Beijing 
2-5 mL Vietnam, South America Several 
13. Sheep brain vaccine (SV)+ 2-5 mL India, Pakistan, Africa Several 
*PDEV contains a preservative and has been approved for intradermal postexposure rabies treatment by the Swiss Government, It is currently being reformulated 
from 1 .O mL to 0.5 mL of diluent. 
+These vaccines are given subcutaneously as 8 to 17 daily injections, usually into the abdominal wall. They should be avoided whenever possible but must be used 
when one of the other products is not available and transporting the patient to a higher level of care immediately is not possible. 
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Following are the postexposure tissue or avian cul- 
ture vaccine regimens currently approved by the WHO: 
1. Conventional intramuscular or “Essen” regimen: this 
consists of one ampule of tissue or avian vaccine (see 
l- 11 in Table 1) given into deltoid or lateral thigh 
muscle on days 0, 3, 7, 14, and 28.* 
2. Reduced-dose intramuscular “2-l-l Ij or “Zagreb” reg- 
imen: this regimen saves one vaccine dose and two 
clinic visits. It consists of two intramuscular doses 
of any tissue or avian vaccine given one on each del- 
toid site on day 0 and one dose at one site on days 
7 and 21.* 
3. Thai Red Cross, “2-site” (“TRC-ID”) intradermal regi- 
men: this should not be used with adjuvanted tissue 
culture vaccines (9-l 1 in Table 1) and never with 
SMB or SV vaccines. It consists of giving 0.1 mL intra- 
dermally at two sites on days 0, 3, and 7 and at one 
site on days 28 and 90. 
4. “Oxford” or “eight-site” intradermal regimen: this 
method consists of 0.1 mL intradermally with tissue 
or avian vaccines (l-9 in Table 1) at eight sites on 
day 0, at four sites on day 7, and at one site on days 
28 and 90 (Table 2).22 
ANTIRABIES SERA AND IMMUNE GLOBULINS 
Human rabies immune globulin is manufactured to WHO 
standards by Cutter in the United States, the Swiss Serum 
and Vaccine Institute in Switzerland, the Institute Merieux 
in France, and the Thai Red Cross National Blood Center 
in Bangkok. Human rabies immune globulin is virtually 
free of side effects and is given as 20 IU/kg. Processing 
eliminates the risk of human immunodeficiency virus 
(HIV) infection. It is expensive and in short supply or 
not available in many parts of the world.25 
Purified equine rabies immune globulin is produced 
to WHO standards by the Institute Pasteur (France), the 
Swiss Serum and Vaccine Institute, and the Thai Red 
Cross. Purified ERIG is ammonium sulfate or alcohol pre- 
cipitated and pepsin digested.** The old unpurified 
equine rabies antisera carried a serum sickness reaction 
rate of up to 40/,. o 24 However, the new purified products 
are safe and have a serum sickness rate of around 1%. A 
recent study confirmed that the skin test, recommended 
prior to injecting ERIG, does not predict serum sickness.*’ 
Anaphylactic reactions due to purified ERIG are no more 
common than with parenteral penicillin where the skin 
test is now rarely, if ever, used in clinical practice.27 How- 
ever, unpurified antirabies sera are still used in some 
developing countries. 
EFFECTIVENESS OF TREATMENT 
How effective ispostexposure rabies treatment, and bow 
can efictiveness be further improved? There is little 
doubt that potent rabies vaccines alone prevent deaths 
in many exposed subjects. The problem, however, is that 
it is not possible to predict which patients will require 
rabies immune globulin (RIG) as well as vaccine, to inac- 
tivate virus at the inoculation sites and to provide pro- 
tection during the first critical week after infection. 
Patients with severe bite wounds and inoculations close 
to or into peripheral nerves, where the virus appears to 
be in an immune protected state, are at particular risk of 
death unless wounds are thoroughly cleansed and infil- 
trated with HRIG or ERIG on the first day of treat- 
ment.6s7,28,29 This concept is substantiated by classic 
animal experiments and recent clinical experience.7J9-31 
Surgical manipulation of bite wounds should be delayed 
until after a good systemic immune response has been 
achieved by vaccination (after at least 7 days).29 If surgi- 
cal closure is unavoidable, it should only be done after 
thorough infiltration of the wounds with immune glob- 
ulin which should be diluted in saline if the calculated 
volume is inadequate to inject all wounds.28-30 Injection 
of infected bite wounds with RIG does not pose added 
risks if carried out after wound cleansing and under 
antibiotic cover.31 Recent experience in Mexico, where 
RIG is virtually unavailable except to the rich, has shown 
that intensive care can occasionally salvage a human with 
rabies but at the expense of permanent severe neuro- 
logic disability.32 
Management of Unusual Human 
Rabies Exposure Cases 
What should be done with humans who have been 
severely exposed to rabies and who have been previ- 
ously started on a vaccine series without RIG? This is 
a common situation in rabies endemic countries where 
RIG is often not widely available, although vaccine may 
be on hand. It is also seen in tourists returning from Asia, 
Africa, or Central and South America. Giving RIG after 
vaccine results in suppression of the endogenous sys- 
temic antibody response, but it is not known to what 
extent this is clinically significant.* A prospective study 
with ERIG given up to 5 days after vaccine had been 
started, did not result in significant suppression of neu- 
tralizing antibodies. 33 It has been suggested that RIG 
should not be given after day 7 when a potent tissue or 
avian vaccine can be expected to have produced 
detectable circulating antibodies.16 However, this rec- 
ommendation has never been confirmed by a prospective 
study in humans who have been severely exposed. 
Medicolegal considerations may make it prudent in some 
such cases to inject the wound sites even after day 7 
following the first dose of vaccine and to start the 
intramuscular or intradermal schedule once more from 
the beginning. This is a common practice in Europe 
when travelers return home with incomplete postexpo- 
sure treatment. 
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What should be done with a patient who has bad 
a remote previous series of brain tissue derived vac- 
cine (SV or SMB) and presents decades later with a 
new exposure? This also is a common problem in many 
developing countries. The staff at Queen Saovabha Memo- 
rial Institute (QSMI) had decided arbitrarily 5 years ago 
to treat such patients as if they had never been vacci- 
nated. This was done largely because the potency of 
some SV and SMB vaccines is not known. This concept 
was tested recently in a prospective study of 98 such 
subjects seen at QSMI. Virtually all (including one lady 
who had received Thai-made Semple vaccine 50 years 
previously) showed immunologic recall with early high 
antibody titers. Some had titers above 0.5 IU/mL on day 
0 prior to re-treatment. However, there was a small group 
of subjects (18%) who behaved as if they were immuno- 
logically naive and, thus, may require RIG to protect them 
during the first critical week after a new severe expo- 
sure. It was not possible to predict which patient would 
not have an accelerated immune response.34 The 
response was not related to age or time elaplsed since 
the previous vaccination. Therefore, it was decided to 
continue the present practice of treating patients with 
remote previous brain tissue derived rabies vaccine treat- 
ment as if they had never been vaccinated. If such 
patients have severe exposures, they receive RIG and a 
full vaccine series. 
What should be done with a subject who has 
incurred a severe rabies exposure and who has received 
a potent tissue culture pre- or postexposure series more 
than 5 years previously? The 1992 WHO rabies techni- 
cal report series suggests that two booster injections of a 
potent tissue or avian vaccine without RIG given on day 
0 and 3 suffice in such cases.* This practice has been fol- 
lowed at QSMI without regret so far A long-term prospec- 
tive study of the immune response in such subjects is 
being conducted, since tissue and avian culture vaccines 
have now been available in Thailand for 2 decades. How- 
ever, if there is any doubt about the prior vaccination his- 
tory or the type or quality of vaccine used or, in the case 
of an exceptionally severe exposure, the patient is treated 
as immunologically naive, with RIG and a complete course 
of intradermal or intramuscular vaccine.29 
What should be done with a patient who has bad 
an exposure and presents for treatment after consid- 
erable delay (weeks to months)? No one knows what 
happens to rabies virus during prolonged incubation peri- 
ods such as were reported from America and Australia.5 
Does the virus reside at the bite site before suddenly 
replicating and migrating centrally; or is it already in 
neural tissue? There is no way to determine whether such 
a patient is Infected and whether he or she is now silently 
incubating the disease. Patients incubating rabies usually 
do not show a detectable antibody response and do not 
have detectable antibodies during the silent phase. This 
concept has, however, never been confirmed in a 
prospective study. Previously not vaccinated human 
rabies cases at QSMI had no detectable rabies antibodies 
when first seen at onset of symptoms6 It may be that a 
patient who comes long after having been bitten or other- 
wise exposed already has replicating virus in an immuno- 
protected intraneural location and that he or she may die 
within days to weeks of consulting the physician. Start- 
ing a postexposure series late would then be futile. Nev- 
ertheless, this is not known for sure and ethical and 
medicolegal considerations mandate that such a patient 
be given full postexposure treatment, including injection 
of wound sites with RIG.* 
What should be done with a severely exposed per- 
son (multiple bites and lacerations usually of the bead, 
neck, andface of a child) where the calculated dose of 
RIG consists of a volume that is insufficient for infil- 
tration of all wounds? This situation is also not uncom- 
mon in countries with large feral dog populations. The 
staff at QSMI sees almost one such patient monthly. The 
nurse practitioners arbitrarily decided in 1993 to dilute 
the RIG in saline to make up an adequate volume for 
proper infiltration of all wounds. This decision was made 
when the staff became aware of the death of a child in 
Thailand where prompt and expert treatment with vac- 
cine and RIG was rendered, but not all wounds could be 
infiltrated.35 Five such well-documented cases were 
reported in I996 as a joint effort from Thailand, India, 
and Sri Lanka.29 Therefore the HRIG or ERIG is diluted to 
make up an adequate volume for careful infiltration of all 
wounds. This recommendation, though not substantiated 
by a prospective study, was incorporated into the 1995 
report of a WHO expert committee conference.28 
What should be done with severe animal bite 
wounds that would, with most other types of injury, 
be closed by primary suture? Any surgical manipulation 
of possibly rabies-infected animal bite wounds increases 
the risk of death. Three of the five children who died of 
rabies, according to the 1996 report from Thailand, India, 
and Sri Lanka, had primary suture before infiltration of the 
wounds with RIG.29 It has also been the experience of 
Thailand’s senior traumatologist that human and animal 
bite wounds are best closed by secondary suture after 
proper cleansing and daily wound care. Infection is much 
less of a problem when this is practiced, and cosmetic 
end-results are better (Bhanganada K. Unpublished). 
Therefore, good daily wound care and secondary closure 
after 1 week is recommended. When primary surgical 
intervention is unavoidable, only the most urgent surgi- 
cal manipulation should be carried out and only after vig- 
orous cleansing and careful infiltration of the wounds 
with RIG.28 The author cannot present any statistically 
sound studies to substantiate these recommendations 
except for the classic animal experiments of Dean and 
Baer3’ and clinical experience in Bangkok. 
In what setting is using one of the intradermal 
rather than an intramuscular postexposure regimen 
140 InternationalJournal ofInfectious Diseases / xr-‘---- ’ ni----L -- 7 T-r----- 1 nn’ 
appropriate? The primary purpose of the intradermal 
schedules is to make high-quality, expensive tissue and 
avian culture vaccines affordable and to enable clinics in 
canine rabies endemic countries to discontinue the use 
of dangerous SV and SMB products. The intradermal reg- 
imen helped Thailand to abolish the manufacture and 
use of SV and SMB in 1!~6.~~ The addition of a preserv- 
ative to the vaccine has also been recommended, since 
this would allow safe storage of the reconstituted vac- 
cine in a refrigerator and use of the remnant in the 
ampule for the next patient? The affordable TRC intra- 
dermal (TRC-ID) regimen is being used increasingly in 
Asia and has found acceptance among nurses who are 
familiar with intradermal injection techniques, since intra- 
dermally injected infant bacille Calmette-G&in (BCG) 
vaccination is the most widely used vaccine worldwide. 
The TRC-ID regimen has now been used in over 80,000 
patients at QSMI since 1986. About 20 to 30% of these 
patients are thought to have had severe bites from rabid 
dogs or cats. There was only one death in this group; an 
elderly alcoholic with severe face, neck, and arm injuries 
who presented for treatment after a 6-day delay, The cal- 
culated volume of ERIG may not have been sufficient to 
inject all wounds adequately in this man.35 The “Oxford” 
or eight-site intradermal regimen is more commonly used 
in Africa. It results in an earlier immune response than 
the conventional intramuscular or Thai Red Cross intra- 
dermal regimens. It has therefore been suggested that 
the immune response with the Oxford schedule may offer 
an advantage and increase survival when no RIG is avail- 
able. However, this hypothesis has not been tested in a 
prospective study. Such a study would be impossible to 
carry out in Thailand or any other country where RIG 
could be made available. One disadvantage of the Oxford 
(and the Zagreb) schedule is that the patient is not rou- 
tinely seen on day 3, the time when most wound infec- 
tions become manifest in tropical countries. 19z31 The cost 
savings of the intradermal schedules can only be attained 
if one is following several patients simultaneously in post- 
exposure or preexposure regimens (unless one uses a 
vaccine with preservative that allows safe storage for 
more than 1 week). The reconstituted vaccine that does 
not contain preservatives should not be stored for more 
than 1 day, and then only if properly refrigerated. How- 
ever, studies have shown that all tissue and avian rabies 
vaccine products are quite stable for at least 1 week after 
reconstitution with the diluent.28~36 
Who Should Receive Preexposure Rabies 
Vaccination? 
Universal preexposure rabies vaccination in canine 
endemic countries such as Thailand has been considered. 
Unfortunately it is not affordable. Even when one assumes 
a probably unrealistically low vaccine cost of US $1 per 
dose, the cost of a human rabies case prevented would 
be over US $150,000 in Thailand (Chutivongse S. Unpub- 
lished). The obvious solution to the rabies problem is 
intensive dog population control and enforcement of dog 
vaccination laws, such as has been done by Malaysia.37 
Preexposure vaccination of selected populations, who are 
more likely to be exposed and who can bear the cost, 
has also been advocated.38 The recommended schedule is 
one intramuscular or intradermal injection (1 ampule or 
0.1 mL, respectively) on days 0, 7, and 28.4 An abbrevi- 
ated method, allowing completion of the regimen within 
1 week, has been proposed recently and consists of three 
full-dose intramuscular injections at three sites on day 1 
with a booster dose on day 7.40 
CHALLENGES FOR THE FUTURE 
A vigorous attack on canine rabies in developing coun- 
tries is in everybody’s interest. However, the current 
approach of organizing occasional dog control and 
Table 2. Management of Rabies Exposure in Rabies Endemic Countries 
Treatment Regimen 
WHO Category Nature of Contact Unknown, Sick, Proven Rabid, 
or Wild Mammal Healthy Animal 
I Petting, feeding, licking on healthy skin, None* None* 
no mucous membrane exposure 
II 
III 
Superficial scratch, lick on broken skin 
Single or multiple transdermal wounds at 
any location, or lick over mucous membrane 
Vaccine Vaccine+ 
RIG plus vaccine RIG plus vaccine+ 
*This is a good time to stat? preexposure vaccination, particularly in children and others likely to have repeated animal contacts, such as postmen, monks, joggers, 
police officers, back-packers, and others more at risk of dog bites. 
+Start full treatment on first day and discontinue vaccine if animal is alive and well on day 10 or if it has been found rabies negative on reliable laboratory examination. 
Encourage patient to return for another vaccine dose on day 28 so that a full preexposure series has been completed. 
RIG: Human rabies immune globulin (HRIG) is given as 20 IU/kg. Equine rabies immune globulin (ERIG) is given as 40 IU/kg. Both are injected into and around all 
wounds with any surplus given by deep intramuscular injection. If the calculated volume is inadequate for the injection of all wounds, dilute it in normal saline to make 
up a sufficient volume. Disregard the old recommendation, still found in most textbooks and on some inserts provided with RIG, that half of the calculated volume of 
RIG should be injected into the wounds and half intramuscularly elsewhere. 
Note: It may be appropriate to double the first dose of vaccine (whatever schedule is used) if there is significant delay in presentation or if the patient is 
immunosuppressed. Administration of two ampules of vaccine, one in each arm, on day 0 with the Essen schedule, intradermal injections into four sites with the Thai 
Red Cross regimen or doubling the dose from 0.1 to 0.2 mL of vaccine with the Oxford regimen on day 0 should be considered in such cases. 
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vaccination campaigns has not been effective in most 
canine rabies endemic regions of the world. Other 
approaches, such as supplementing parenteral dog immu- 
nization programs with regular oral vaccination of feral 
dogs, should be investigated in earnest. An alternative 
that should be within reach would be to develop long- 
acting repository animal rabies vaccines likely to produce 
lasting immunity with one injection. The manufacture of 
equine rabies immune globulin needs to be encouraged, 
possibly by state subsidies where needed in order to 
make low-cost ERIG more widely available.25 The tech- 
nology is the same as that used by many snake farms that 
produce purified snake antivenoms, and by blood banks 
that manufacture plasma fractions. If horses are handled 
in a humane manner and plasmapheresis is used, a few 
such animals with a normal life expectancy can provide 
a whole country with ERIG. The often well-organized 
and publicized efforts of so-called animal rights groups, 
who have pressured for closure of horse farms used in 
the production of equine origin antisera for rabies, snake- 
bite, tetanus, and diphtheria have to be countered. There 
are as yet no affordable and practical substitutes for these 
life-saving biologicals.2j Even the most recent editions of 
respected American medical textbooks, used worldwide 
by students and practitioners, discuss rabies only from the 
Western, “a very rare disease,” point of view.39,41 These 
books neglect to mention the different approach to risk 
assessment of dog and cat bites in canine rabies endemic 
parts of the world. The availability of effective and safe 
second generation rabies tissue and avian culture vac- 
cines and the much improved safety of ERIG are not dis- 
cussed. This neglect has led to serious management 
errors. Examples noted by the author have been: obser- 
vation of a biting dog in a canine rabies endemic region 
when immediate start of a full postexposure treatment 
regimen was indicated, delay in treatment when a patient 
was advised by telephone by his family doctor in Amer- 
ica to wait till he or she returned home where HDCV 
and HRIG could be administered. That, even though inex- 
pensive safe and effective PCEC, PVRV, or PDEV’ and puri- 
fied ERIG were readily available locally. 
Post exposure treatment of dogs exposed to rabies 
has been discouraged by WIIO.4 Such dogs are to be quar- 
antined for prolonged periods or destroyed. This rec- 
ommendation has been largely disregarded by owners 
who will not agree to destruction or prolonged isolation 
of their pet. Blancou and Aubert carried out challenge 
studies with “human-like” postexposure treatment in ani- 
mals and demonstrated effectiveness.42 The veterinary 
rabies diagnostic clinic at QSMI in Bangkok has been 
encountering rabies-exposed pet dogs for years. It has 
been the policy of the clinic to encourage euthanasia or 
quarantine. If the owner refuses, a human-like postex- 
posure vaccine regimen that includes injection of wounds 
with ERIG (40 IU/kg) and intramuscular vaccination 
(using a veterinary tissue culture product) on days 0, 3, 
7, 14, and 28 is offered. The animal is restricted to the 
owner’s compound and all members of the family and ser- 
vants are given preexposure rabies vaccine. Experience 
so far with I6 dogs has been satisfactory and the study 
is continuing (Tepsumethanon W, Mitmoonpitak C, 
Lumlertdaecha B. Unpublished). 
One bright note for owners of dogs and cats who 
wish to relocate their pets to countries that are rabies 
free and where long and costly quarantine regulations 
have been a barrier, is that new regulations could abol- 
ish quarantine. Blancou and Aubert have demonstrated 
that if a dog owner presents a reliable vaccination cer- 
tificate and it can be shown that there is a satisfactory 
neutralizing rabies antibody titer, there is no risk of the 
animal incubating rabies.42 On the basis of this evidence, 
public health authorities in rabies-free Sweden, Norway, 
Finland, and New-Caledonia have already changed their 
quarantine regulations, and other countries are expected 
to follow. 
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